Eurofins Scientific/€ERF
05:30
09:10
12:45
16:25
20:00
1D1W1MYTD1Y5YMAX
About Eurofins Scientific
Eurofins Scientific, with the ticker ERF, is a global bio-analytical testing providing services across several industries including pharmaceutical, food, environmental, and consumer products. Founded in 1987, the company specializes in delivering analytical testing and advisory services to ensure product safety and compliance with regulations. Eurofins operates through a decentralized network of laboratories, serving customers worldwide to enhance health and safety standards.
Ticker
€ERF
Sector
Primary listing
PAR
Employees
65,000
Headquarters
Luxembourg City, Luxembourg
Website
ERF Metrics
BasicAdvanced
€11B
31.52
€1.98
0.77
€0.60
0.96%
Price and volume
Market cap
€11B
Beta
0.77
52-week high
€69.42
52-week low
€44.52
Average daily volume
1.2K
Dividend rate
€0.60
Financial strength
Current ratio
1.256
Quick ratio
1.084
Long term debt to equity
76.534
Total debt to equity
88.054
Dividend payout ratio (TTM)
60.00%
Interest coverage (TTM)
6.48%
Profitability
EBITDA (TTM)
1,490.4
Gross margin (TTM)
22.59%
Net profit margin (TTM)
6.05%
Operating margin (TTM)
13.45%
Effective tax rate (TTM)
27.90%
Revenue per employee (TTM)
€110,000
Management effectiveness
Return on assets (TTM)
5.62%
Return on equity (TTM)
8.67%
Valuation
Price to earnings (TTM)
31.525
Price to revenue (TTM)
1.622
Price to book
3.26
Price to tangible book (TTM)
-5.95
Price to free cash flow (TTM)
14.756
Free cash flow yield (TTM)
6.78%
Free cash flow per share (TTM)
4.24
Dividend yield (TTM)
0.96%
Forward dividend yield
0.96%
Growth
Revenue change (TTM)
6.25%
Earnings per share change (TTM)
14.62%
3-year revenue growth (CAGR)
1.38%
10-year revenue growth (CAGR)
16.08%
3-year earnings per share growth (CAGR)
-14.72%
10-year earnings per share growth (CAGR)
14.69%
3-year dividend per share growth (CAGR)
-15.66%
10-year dividend per share growth (CAGR)
16.35%
What the Analysts think about ERF
Analyst ratings (Buy, Hold, Sell) for Eurofins Scientific stock.
Bulls say / Bears say
In H1 2025, Eurofins delivered record revenues of €3.612 billion, up 5.7% year-on-year, with adjusted EBITDA rising 7% to €810 million and margins improving to 22.4%, reflecting resilient demand and operational efficiencies (Reuters).
Eurofins closed 22 bolt-on acquisitions in H1 2025, adding over €210 million of pro-forma revenues at an attractive average multiple of 0.75×, including the acquisition of SYNLAB’s Spanish clinical diagnostics business, bolstering its global lab network (Company Regulatory News).
The company secured €500 million in 7.5-year senior unsecured bonds at a 3.875% coupon, over-subscribed eightfold, demonstrating strong capital market support for its strategy to acquire related-party sites and finance growth initiatives (BusinessWire).
Net debt to EBITDA climbed to 2.1× as of June 2025, up from 1.9× at year-end 2024, approaching the upper bound of its 1.5×–2.5× mid-term leverage target and increasing vulnerability to interest rate fluctuations (Company Regulatory News).
HSBC downgraded Eurofins to a Hold rating in April 2025 and cut its price target to €48, citing underperformance in the North American biopharma segment and concerns over organic growth trailing medium-term targets (Boursorama/Reuters).
To meet full-year free cash flow objectives, Eurofins must generate over €600 million in H2 2025 versus €354 million in H1, posing execution risk if cash conversion in the second half falls short (Investing.com).
Data summarised monthly by Lightyear AI. Last updated on 8 Sept 2025.
ERF Financial Performance
Revenues and expenses
ERF Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Eurofins Scientific stock?
Eurofins Scientific (ERF) has a market cap of €11B as of September 18, 2025.
What is the P/E ratio for Eurofins Scientific stock?
The price to earnings (P/E) ratio for Eurofins Scientific (ERF) stock is 31.52 as of September 18, 2025.
Does Eurofins Scientific stock pay dividends?
Yes, the Eurofins Scientific (ERF) stock pays dividends to shareholders. As of September 18, 2025, the dividend rate is €0.6 and the yield is 0.96%. Eurofins Scientific has a payout ratio of 60% on a trailing twelve-month basis.
When is the next Eurofins Scientific dividend payment date?
The next Eurofins Scientific (ERF) dividend payment date is unconfirmed.
What is the beta indicator for Eurofins Scientific?
Eurofins Scientific (ERF) has a beta rating of 0.77. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.